Related Experiment Videos
Increased extraction of endothelin-1 across the failing human heart
E R Azevedo1, D J Stewart, J D Parker
1Mount Sinai Hospital, Division of Cardiology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
The American Journal of Cardiology
|July 13, 2001
Insights
Plasma endothelin-1 levels decrease across the failing human heart, but not in hearts with normal function. This study highlights endothelin-1
Area of Science:
- Cardiovascular Physiology
- Endocrinology
- Heart Failure Pathophysiology
Background:
- Endothelin-1 is a potent vasoconstrictor peptide implicated in cardiovascular diseases.
- Congestive heart failure is associated with complex neurohormonal alterations.
- Understanding endothelin-1 dynamics in heart failure is crucial for therapeutic development.
Purpose of the Study:
- To investigate the transcardiac gradient of plasma endothelin-1 in patients with congestive heart failure.
- To compare endothelin-1 levels in failing hearts versus hearts with normal ventricular function.
Main Methods:
- Measurement of plasma endothelin-1 levels.
- Comparison of arterial and venous endothelin-1 concentrations across the heart.
- Patient groups included those with congestive heart failure and those with normal left ventricular function.
Main Results:
- A significant reduction in plasma endothelin-1 was observed across the failing human heart.
- This reduction in endothelin-1 was not evident in patients with normal left ventricular function.
- The findings suggest myocardial extraction or metabolism of endothelin-1 in heart failure.
Conclusions:
- The failing human heart actively reduces plasma endothelin-1 levels.
- Endothelin-1 may play a role in the pathophysiology of heart failure beyond vasoconstriction.
- Further research is warranted to elucidate the mechanisms and clinical implications of this endothelin-1 gradient.
Abstract:
In this study we compared the transcardiac gradient of plasma endothelin-1 in patients with normal ventricular function and in those with congestive heart failure. We documented a significant reduction in the plasma levels of endothelin-1 across the failing human heart, an effect not seen in patients with normal left ventricular function.